Moderna, Inc. (MUN:0QF)
Germany · Delayed Price · Currency is EUR | Market Cap | 19.76B +112.4% |
| Revenue (ttm) | 1.95B -27.6% |
| Net Income | -2.76B |
| EPS | -7.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 513 |
| Open | 49.23 |
| Previous Close | 49.41 |
| Day's Range | 49.23 - 50.85 |
| 52-Week Range | 20.18 - 71.88 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine
Moderna's vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.
Moderna announces initiation of Phase 1 trial of mRNA-1469
Moderna (MRNA) announced that following Health Canada’s authorization of the study, the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating mRNA-1469, the Company’...
Moderna begins first human trial of Bundibugyo Ebola vaccine
Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to protect against Bundibugyo ebolavirus, a strain of Ebola that has killed more than 1,650 people so far and cu...
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines indicated Phase 1 trial is being conducted in Canada as part of our expanded collab...
Moderna price target raised to $60 from $41 at Citi
Citi raised the firm’s price target on Moderna (MRNA) to $60 from $41 and keeps a Neutral rating on the shares. The firm updated models in the biotechnology space post…
Moderna Wins a Post-COVID Earnings Beat as Analyst Eyes ‘Clinically Meaningful’ Trial Results
Moderna’s ($MRNA) latest earnings were better-than-expected. Jefferies ($JEF) analyst Andrew Tsai explained that while quarterly earnings beat expectations, new data from cancer treatments will show w...
Moderna Earnings Call Transcript: Q2 2026
Q2 2026 revenue exceeded guidance at $145 million, with improved cost discipline and a net loss of $782 million. Pipeline advanced with key regulatory milestones in flu and RSV vaccines, and oncology programs showed durable benefit. Revenue growth of up to 10% is expected for 2026.
Moderna Earnings release: Q2 2026
Moderna released its Q2 2026 earnings on July 31, 2026, summarizing the period's financial results.
Moderna Slides: Q2 2026
Moderna has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 31, 2026.
Moderna Quarterly report: Q2 2026
Moderna has published its Q2 2026 quarterly earnings report on July 31, 2026.
Moderna Narrows Loss, Says New Norovirus Vaccine Didn't Meet Expectations
Moderna narrowed its loss in the recent quarter as revenue climbed, boosted by deliveries made under a government contract in the U.K.
Moderna Earnings Are Better Than Expected So Why Is the Stock Falling?
The drugmaker's top line continues to be heavily influenced by Covid vaccine sales.
Moderna sees FY26 cost of sales $1.7B, down from prior $1.8B view
The company is targeting up to 10% growth from 2025 revenue and expects 2026 revenue split to be approximately 50% U.S. and approximately 50% international. Moderna (MRNA) expects approximately 55%…
Moderna sees potential approval of fifth product for mFLUSIVA
The company anticipates potential approval of Moderna’s (MRNA) fifth product with the August 5th PDUFA date for mFLUSIVA, the company’s seasonal influenza vaccine candidate.
Moderna reports Q2 EPS ($1.97), consensus ($2.06)
Reports Q2 revenue $145M, consensus $103.88M. “The second quarter marked another period of strong execution for Moderna (MRNA) as we advanced our pipeline and strengthened our financial profile with a...
Moderna affirms FY26 revenue view of $2.14B, consensus $2.09B
07:02 EDT Moderna (MRNA) affirms FY26 revenue view of $2.14B, consensus $2.09B
Moderna says mRNA-1403 didn’t meet criteria for early success
Moderna (MRNA) said its Phase 3 safety and efficacy study of mRNA-1403 did not meet statistical criteria for early success at the Phase 3 interim analysis. The trial is ongoing…
Moderna misses quarterly revenue estimates on COVID vaccine weakness
Moderna missed Wall Street estimates for second-quarter revenue on Friday, hit by weaker-than-expected sales of its COVID-19 shot, ahead of an upcoming regulatory decision for its experimenta...
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97) Reiterates plan to deliver up to 10% revenue growth in 2026 Improves 2026 GAAP operating expense...
Polymarket Odds: Will MRNA, XOM, CVX Beat Earnings Tomorrow?
On Friday, July 31, Moderna ($MRNA), Exxon Mobil ($XOM), and Chevron ($CVX) will release their earnings. All three companies will report before the market opens. Traders are already weighing in…
Moderna price target raised to $67 from $49 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Moderna (MRNA) to $67 from $49 and keeps a Neutral rating on the shares.
Moderna announces first participant dosed in Phase 1 trial of mRNA-4200
Moderna (MRNA) announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic ...
Arbutus Biopharma receives $178M settlement agreement from Moderna
Arbutus (ABUS) also announced the receipt of approximately $178M from Moderna (MRNA), representing the company’s share of the noncontingent payment under the settlement agreement entered into with Mod...
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cance...